Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3. Widmark A, et al. Among authors: tasdemir i. Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Epub 2008 Dec 16. Lancet. 2009. PMID: 19091394 Free article. Clinical Trial.
Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial.
Solberg A, Widmark A, Tasdemir I, Ahlgren G, Angelsen A. Solberg A, et al. Among authors: tasdemir i. Scand J Urol Nephrol. 2011 Sep;45(4):233-8. doi: 10.3109/00365599.2011.560577. Epub 2011 Mar 31. Scand J Urol Nephrol. 2011. PMID: 21452932 Clinical Trial.
5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer.
Hemdan T, Johansson R, Jahnson S, Hellström P, Tasdemir I, Malmström PU; Members of the Urothelial Cancer Group of the Nordic Association of Urology. Hemdan T, et al. Among authors: tasdemir i. J Urol. 2014 May;191(5):1244-9. doi: 10.1016/j.juro.2013.11.005. Epub 2013 Nov 11. J Urol. 2014. PMID: 24231843 Clinical Trial.
Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.
Iversen P, Johansson JE, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong J; Scandinavian Prostate Cancer Group. Iversen P, et al. Among authors: tasdemir i. Scand J Urol Nephrol. 2006;40(6):441-52. doi: 10.1080/00365590601017329. Scand J Urol Nephrol. 2006. PMID: 17130095 Clinical Trial.
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.
Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K; Scandinavian Prostatic Cancer Group. Iversen P, et al. Among authors: tasdemir i. J Urol. 2004 Nov;172(5 Pt 1):1871-6. doi: 10.1097/01.ju.0000139719.99825.54. J Urol. 2004. PMID: 15540741 Clinical Trial.
62 results